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Autoimmunity against the Goodpasture antigen
a3IV-NC1 results in antiglomerular basement membrane
glomerulonephritis. Although antibodies are central to the
pathogenesis, there is good evidence for the participation
of T cells in this disease. To define the contribution of
T cells, we used the model of experimental autoimmune
glomerulonephritis. Immunization of DBA/1 mice with
a3IV-NC1 resulted in proteinuria, a biphasic course of the
disease, and an eventual loss of kidney function. In the
initial phase, the mice developed an a3IV-NC1-specific IgG
response, had IgG deposition along the glomerular basement
membrane, and steadily increased proteinuria, but only
marginal signs of inflammation with limited leukocyte
infiltration. After 9–13 weeks, mice proceeded to develop
crescentic glomerulonephritis, extensive tubulointerstitial
damage, and massive macrophage infiltration. T-cell
infiltration was less pronounced, mostly confined to the
interstitium, and T cells displayed an activated phenotype
with a significant fraction of Th1 or Th17 CD4þ T cells. Close
examination revealed the presence of autoreactive T cells
producing IFNc upon restimulation with a3IV-NC1. Thus,
our results suggest that accumulation of effector T cells,
including autoreactive T cells, represents a critical step in the
progression from mild glomerulonephritis, with limited
glomerular damage, to severe crescentic glomerulonephritis
accompanied by tubulointerstitial inflammation and loss of
kidney function.
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Autoimmunity against the Goodpasture antigen results in
antiglomerular basement membrane (GBM) glomerulo-
nephritis (GN).1–4 Deposition of pathogenic autoantibodies
along the GBM is the hallmark feature in this form of rapidly
progressive GN.5 Antibodies recognize conformational epi-
topes in the C-terminal non-collagenous NC1 domains of the
a3-chain and the a5-chain of type IV collagen (a3IV-NC1 or
a5IV-NC1, respectively). Antibodies bind to two distinct
epitopes in a3IV-NC1 and to a single epitope in a5IV-NC1.6
Under steady-state conditions, these epitopes are fairly
inaccessible but may become exposed under inflammatory
conditions. Antibody binding results in disruption of the
quaternary collagen structure, destabilization of the basement
membrane, and increased exposure of additional epitopes.7–9
Currently, it is not known how necrotizing GN is subse-
quently initiated. Complement activation may have a role,
but it is possible that an additional insult, potentially
mediated by leukocytes, is necessary.
Evidence from both patients and experimental models
implicates a major contribution of the cell-mediated immune
response in the development and progression of anti-GBM
disease.4,10–14 However, direct evidence for the recruitment
and activation of a3IV-NC1-specific cells in the kidneys is
still lacking, largely because it is a major challenge to assess
small antigen-specific T-cell populations from human or
animal kidneys.
The experimental autoimmune GN (EAG) animal model
recapitulates many features of human anti-GBM disease and
allows the study of antigen-specific cellular immune mechan-
isms in crescentic GN.15–24 EAG can be induced in susceptible
DBA/1 mice by repeated immunization with recombinant
human a3IV-NC1 produced in human embryonic kidney
293 cells. Mice mount B- and T-cell responses against
a3IV-NC1 and develop overt clinical disease by 3 months.25
The aim of our study was to characterize the T-cell re-
sponse in the kidneys of EAG mice. We could demonstrate a
biphasic course of the disease. Although interferon (IFN)gþ
T cells are already present in the ‘preclinical’ phase with only
a mild GN, both IFNgþ and interleukin (IL)-17Aþ T cells,
including a3IV-NC1-specific T-helper (Th)1 cells, are found
in the ‘clinical’ phase with crescentic GN. Our results suggest
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that T cells are not only involved in the induction of auto-
antibodies but also actively participate in renal destruction in
the final stage of EAG.
RESULTS
EAG induced in DBA/1 mice
Repeated immunization of DBA/1J mice with recombinant
human a3IV-NC1 led to clinical signs of EAG in 25/26 mice
after 9–13 weeks. By contrast, DBA/1J mice treated with
adjuvant only did not show any sign of the disease over the
whole observation period (Figure 1a). Proteinuria was first
detected at 6–7 weeks, becoming nephrotic in most animals
by week 8–9 (Figure 1b). Mice with severe clinical symptoms
of EAG were killed and further assessed for kidney and lung
pathology. Results from analyses of mice killed owing to severe
disease were combined and are presented throughout the
article as ‘EAG’ mice. EAG mice had significantly elevated
serum blood urea nitrogen (BUN) levels (Figure 1c, median
30.5 vs. 60.4 mg/dl; Po0.001). Kidney histology revealed severe
crescentic GN (Figures 1d and 2a–d, median % crescents 52.5
in EAG mice vs. 0 in controls; Po0.001) and most EAG mice
developed extensive tubulointerstitial damage (Figures 1e
and 2a,b, median score 2.75 vs. 0.00; Po0.001). Frequent
glomerular necrosis and fibrin exudates into Bowman’s capsule
pointed to a high activity of the GN. We did not observe any
correlation of crescent formation, tubulointerstitial damage, or
BUN levels with the time point of sacrifice (Figure 1f and data
not shown), suggesting that the progression from mild disease
to acute renal failure is not a continuously accelerating process
but rather a rapid event with different time points of onset and
kinetics for individual mice. In 3/26 mice with severe EAG,
mild pulmonary disease could be detected (Figure 2e).
Time course of kidney pathology
To study the disease course of EAG in DBA/1 mice, renal
histology was assessed at weeks 3, 5, 7, 8, and 10 after the
primary immunization. We did not detect crescent formation
or fibrin precipitates at 3 and 5 weeks and saw o1%
glomerular crescents at weeks 7 and 8 compared with 52.5%
in EAG mice (Figure 1d, Po0.05). Similarly, tubulointer-
stitial damage was not present until week 7 and was only
marginal at 8 weeks (Figure 1e, Po0.05). In a group of mice
studied at 10 weeks, clinical symptoms correlated with the
severity of pathological findings. In all, 3/3 mice with overt
clinical disease had 45% crescents, a tubulointerstitial
damage score 41.5, and 1/3 mice had an elevated BUN
level. By contrast, only 2/7 mice without clinical symptoms
showed crescents in 45% of the glomeruli; the tubulointer-
stitial damage score of all of these mice was o1.5, and BUN
level was in the range of the control group. Thus, in contrast
to proteinuria, severe renal destruction was a late event
culminating only at the final stage of EAG.
Antibody response in DBA/1 mice
Serum antibodies against human a3IV-NC1 were first detect-
able 2 weeks after primary immunization and high titers
were present from week 4 onwards (Figure 3a, Po0.005).
Antibodies showed strong crossreactivity with recombinant
mouse a3IV-NC1 (Figure 3b, Po0.005). By immunohisto-
chemistry and immunofluorescence, a granular, mostly
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Figure 1 | Experimental autoimmune glomerulonephritis (EAG) in DBA/1 mice. (a) Time point of first clinical signs of EAG according
to a stress score (a3IV-NC1-immunized vs. mock-immunized mice: Po0.001). (b) Albumin in urine normalized to creatinine (maximum of
detection 1000 (g/g)). (c) Blood urea nitrogen (BUN) from mice analyzed at 8 and 10 weeks post immunization as well as from EAG
mice (control vs. EAG, Po0.01). (d) Crescent count on periodic acid–Schiff-stained paraffin sections (control and weeks 3, 5, 7, and 8 vs. EAG:
Po0.05). (e) Assessment of tubulointerstitial (tub-int) damage using a semiquantitative score (control and weeks 3, 5, 7, and 8 vs. EAG:
Po0.05). (f) Linear regression analysis of crescent formation vs. time point of sacrifice (r2¼ 0.0561, P¼NS (not significant)) (b–f: each symbol
represents data of an individual mouse; the bar gives the median).
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segmental immunoglobulin (Ig)G deposition along the GBM
was evident at 5 weeks, and from 7 weeks on mice displayed
moderate to strong global IgG deposition (Figures 2f, 3c,
and d). Consistent with the granular staining pattern, sub-
epithelial electron-dense deposits were detected by trans-
mission electron microscopy (data not shown and Hopfer
et al.25). Isotype analysis of antibodies from serum and
kidney eluates revealed a3IV-NC1-specific IgG1, IgG2a,
and IgG2b, with IgG1 showing the highest titers (data
not shown and Hopfer et al.25). In accordance with this
observation, glomerular deposition of all three isotypes
was detected by immunohistochemistry (data not shown).
IgG deposition along the GBM was accompanied by
the deposition of complement C3, indicating complement
activation (Figure 3e and f). Elevated levels of circulating
immune complexes could not be detected at any time point
with a C1q-based immune complex capture assay (Figure 3g).
These findings suggested that antibody production and
in-situ immune complex formation along the GBM preceded
crescentic GN by several weeks.
Macrophage infiltration in EAG kidneys
Characterization of the cellular infiltrate in mice with
final EAG by immunohistochemistry revealed an increased
number of MAC2þ macrophages within the glomeruli
(Figure 4a; median no. of MAC2þ cells/100 glomerular
cross sections: 77 vs. 10; Po0.01) as well as a vigorous
increase in F4/80þ cells within the interstitium (Figures 2g, h
and 4b, % F4/80þ cortical area 5.76 vs. 0.19; Po0.0005).
Fluorescence-activated cell sorting analysis confirmed the
massive renal infiltration by CD45þ CD11bþ F4/80high cells
in mice with symptoms of EAG. These cells demonstrated
high expression of F4/80 and CD11b and low to intermediary
expression of Gr-1 and Ly6c (Figure 4c and data not
shown). In kidneys from EAG mice, F4/80high CD11bþ cells
represented up to 80% of all CD45þ leukocytes (Figure 4d).
To estimate the extent of kidney infiltration, we calculated
the frequency of CD11bþ F4/80high cells among all events
(CD45þ and CD45) acquired from kidneys by flow cytom-
etry. In mice with EAG, up to 20% of all events from the
kidney were F4/80high CD11bþ cells, compared with values
of 2% in healthy mice (Figure 4d). In line with the absence of
gross renal damage at early stages of disease, frequencies of
renal macrophages remained at the level of controls at 3, 5,
and 7 weeks post immunization (Figure 4d, mean±s.d.:
naive, 2.0±0.5%; week 3, 1.5±0.3%; week 5, 1.5±1.0%;
week 7, 1.4±1.1%; EAG, 12.7±5.9%; Po0.01 for all time
points against EAG). Granulocytes (CD11bhigh Gr-1high
F4/80low) were detected at frequencies of approximately 10
and 2% of CD11bþCD45þ leukocytes in kidneys of control
and EAG mice, respectively (Figure 4c). When calculated for
all acquired events, granulocytes remained at a very low level
(o2%) over the complete observation period and did not
accumulate at the final stage (not shown). Frequencies of
macrophages and granulocytes did not differ in spleens and
lungs of healthy and EAG mice (Figure 4d and not shown).
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Figure 2 |Histological findings in experimental autoimmune
glomerulonephritis (EAG) mice. (a–d) Medium and high power
magnifications of crescentic glomerulonephritis accompanied
by tubulointerstitial damage in EAG mice (b, d) and normal
kidney histology in control mice (a, c). (e) Focal pulmonary
necrosis in some EAG mice. (f) Immunoglobulin (Ig)G deposition
along the glomerular basement membranes (GBMs) in EAG mice.
Note segmental GBM ruptures. (g, h) Immunohistochemistry
revealing F4/80þ macrophages cells in EAG (h), but not control
kidneys (g). (i, j) Immunohistochemistry showing infiltration of
the kidney by CD3þ T cells in EAG (j) and control mice (i).
(a–d: periodic acid–Schiff stain, original magnification  100 or
 600; e: hematoxylin and eosin stain, original magnification
 200; f–j: immunohistochemistry of paraffin section, original
magnification  600 or  400.)
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T-cell infiltration in EAG kidneys
Immunohistochemistry revealed a fourfold increase in
tubulointerstitial CD3þ T cells in mice with EAG (Figures
2i, j and 5a; median no. of CD3þ cells/mm2 of cortex:
58 in EAG kidneys vs. 16 in control kidneys; Po0.001). At 10
weeks, the numbers of interstitial CD3þ cells were already
enhanced (median no. CD3þ cells/mm2 of cortex: 49; 10 weeks
vs. control Po0.01). In contrast to cortical CD3þ cells,
glomerular CD3þ cells were rare in EAG and control mice
(Figure 5b, median no. of CD3þ cells/100 glomerular cross
sections: 6 (control) vs. 10 (10 weeks) vs. 9 (EAG); P¼NS).
Fluorescence-activated cell sorting analysis showed that in
contrast to macrophages, CD4þ and CD8þ T cells repre-
sented only a small fraction of CD45þ cells or of all acquired
events in EAG kidneys (Figure 5c and data not shown).
CD4þ T-cell frequencies remained at low levels at early time
points post immunization and only at the final stage of
disease an increase in renal CD4þ T cells was detected
(Figure 5c, CD4þ cells of all events: mean±s.d.: naive,
0.26±0.07%; week 3, 0.13±0.05%; week 5, 0.17±0.06%;
week 7, 0.19±0.10%; EAG, 0.73±0.35%; Po0.01 for all
time points against EAG). CD8þ T cells remained at low
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Figure 3 | a3IV-NC1-specific serum antibodies, glomerular immunoglobulin (Ig)G and C3 deposition, and circulating immune
complexes (IC). (a) Indirect enzyme-linked immunosorbent assay (ELISA) of human (h) a3IV-NC1-specific IgG in serum, Po0.005 for all
time points. (b) Crossreactivity of a3IV-NC1-specific IgG to mouse (m) a3IV-NC1, Po0.005. (c) Semiquantitative evaluation of IgG
immunofluorescence to assess glomerular IgG deposition. (d) Representative pictures of glomerular IgG deposition from mice analyzed
at 3, 5, and 7 weeks and from experimental autoimmune glomerulonephritis (EAG) mice. Note granular glomerular basement membrane
(GBM) staining (inset). (e) Representative pictures of glomerular C3 deposition. (f) Semiquantitative scoring of C3 immunofluorescence.
(g) ELISA specific for circulating IC (IgM, IgG, and IgA) in mouse serum, P¼NS. a, b, and g: Each circle represents data of an individual
mouse; the bar gives the median. c, f: For each time point kidneys from 4–10 mice were analyzed. Bars show the mean and standard
deviation of % glomeruli in the four categories. d, e: Direct immunofluorescence of cryo sections, original magnification  400.
Kidney International (2012) 82, 60–71 63
H Hopfer et al.: Renal CD4þ T cells in EAG o r ig ina l a r t i c l e
frequencies over the whole observation period (CD8þ cells
of all events: mean±s.d.: naive, 0.08±0.02%; week 3, 0.06±
0.01%; week 5, 0.05±0.02%; week 7, 0.05±0.02%; EAG,
0.13±0.07%; P¼NS).
Directional T-cell trafficking is mainly regulated by
chemokines and specific subsets are attracted owing to
differential surface expression of chemokine receptors. By
real-time PCR, there was a marked upregulation of the
mRNA for Th1 cell–attracting chemokines MIP-1 (macro-
phage inflammatory protein-1)a/CCL3, MIP-1b/CCL4,
and RANTES/CCL5 (acting through chemokine receptor
CCR5; Figure 5d) and less pronounced for MIG/CXCL9
and IP10/CXCL10 (acting through CXCR3) in mice with
EAG. Messages of the corresponding chemokine receptors
CCR5 and CXCR3 were significantly increased as well
(Figure 5D). By contrast, renal mRNA expression of Th2-
attracting chemokines, such as eotaxin/CCL11 (acting
through CCR3) or TARC/CCL17 (acting through CCR4),
was not detectable (data not shown).
Phenotypical and functional characterization of renal T cells
Surface expression of CD44 and CD62L allows the discrimi-
nation of naı¨ve (CD44low CD62Lþ ), central memory
(CD44high CD62Lþ ), and effector, as well as effector memory
T cells (CD44high CD62L). Kidneys of control mice
contained already a large fraction of effector CD4þ and
CD8þ cells when compared with spleens from these animals
(Figure 6a and data not shown). In mice with EAG, almost all
CD4þ and CD8þ T cells displayed the phenotype of effector
T cells. By contrast, spleens, lungs, and blood of control and
EAG mice showed a similar distribution of different T-cell
subsets throughout the observation period, indicating a
restricted accumulation of highly activated T cells in the
kidney (Figure 6a and data not shown). Notably, the distinct
phenotype of renal T cells, which significantly differs from
the phenotype of cells from spleen or blood, also indicates
that our renal cell population contains only minor contami-
nations of cells from the circulation.
T cells isolated from the spleen, kidney, and lung of
immunized mice were incubated with the phorbolester
phorbol 12-myristate 13-acetate and the calcium ionophore
ionomycin to determine the cytokine profile after polyclonal
stimulation. Intracellular staining revealed the presence of
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Figure 4 |Renal macrophages in experimental autoimmune
glomerulonephritis (EAG). (a) Quantification of immuno-
histochemical MAC2 staining expressed as number of MAC2þ
cells per 100 glomerular cross sections (Po0.01). (b) Morphometry
of F4/80 immunohistochemistry (Po0005). (c) Fluorescence-
activated cell sorting (FACS) analysis of renal cells. Cells were
characterized for CD45, CD11b, F4/80, and Gr-1 expression. Blots
show CD45þ CD11bhigh cells of tissues from individual mice.
Numbers give %-values for macrophages (F4/80þ Gr-1low) and
granulocytes (F4/80low Gr-1high) calculated for myeloid cells
(CD11bþ CD45þ ). (d) Distribution of macrophages (CD11bþ
F4/80þ Gr-1low) in relation to CD45þ leukocytes (left panel; naı¨ve,
week 3, and week 5 vs. EAG Po0.05 for macrophages in the
kidney) or in relation to all acquired events (right panel: all time
points vs. EAG Po0.01 for macrophages in the kidney) (c:
representative dot blots; a, b, d: symbols represent data from
individually analyzed mice; the bar gives the median).
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Th1 and Th17 cells, as indicated by the expression of
the hallmark cytokines IFNg and IL-17A in CD4þ T cells
(Figure 6b and c). In the spleen and lung, frequencies of
IFNg- and IL-17A-producing cells remained at a stable level
throughout the time course of observation. Kidneys of
healthy mice contained only low frequencies of IFNgþ Th1
cells; however, post-immunization frequencies were increased
throughout the observation period. By contrast, frequencies
of IL-17Aþ Th17 cells remained at low levels and only at the
final stage of EAG a pronounced increase in the frequency
of these cells was detected (mean %-value±s.d. of IFNgþ
cells among renal CD4þ T cells: naive, 0.1±0.1% vs EAG,
2.7±2.5%; Po0.05; mean %-value ±s.d. of IL-17Aþ cells
among renal CD4þ T cells: naive, 0.2±0.4% vs EAG, 3.6±
2.3%; Po0.01).
Detection of elevated frequencies of Th1 and Th17 cells in
EAG kidneys was accompanied by significantly enhanced
mRNA levels for IFNg and IL-17A (Figure 6d, Po0.05). This
result suggests that accumulation of Th1 and Th17 cells
was accompanied by enhanced local cytokine production,
although we cannot exclude sources other than Th1 or Th17
cells for IL-17A and IFNg.
EAG kidneys contain a3IV-NC1-specific T cells
Our results indicate the accumulation of highly activated
CD4þ T cells in EAG and a fraction of these could be defined
as Th1 and Th17 cells. However, polyclonal stimulation does
not allow conclusions on the specificity of T cells. To analyze
specific T-cell responses, T cells were isolated from kidneys
and restimulated in vitro with a3IV-NC1 in the presence of
professional antigen-presenting cells isolated from naive
DBA/1 spleens (Figure 7a). Specific response was determined
with an IFNg Elispot assay, which proved to be superior in
sensitivity when compared with fluorescence-activated cell
sorting-based assays. Following restimulation of renal cells
from EAG mice with a3IV-NC1, we observed significantly
enhanced numbers of IFNg spots when compared with
cultures without restimulation or following restimulation
with the related but irrelevant collagen peptides a1IV-NC1 or
a2IV-NC1 (Figure 7b, median DIFNg spots 53.0 vs. 15.3 vs.
9.7, Po0.05). There was no difference in the response of
unstimulated, a1IV-NC1-, or a2IV-NC1-stimulated renal
cells. T cells isolated from phosphate-buffered saline (PBS)-
immunized control mice and restimulated with a3IV-NC1 in
the presence of antigen-presenting cells showed significantly
less IFNg spots when compared with similarly treated
cells from EAG mice (median DIFNg spots 6.8; Po0.01).
There was a nonsignificant trend for more IFNg spots in
unstimulated T cells isolated from EAG kidneys as compared
with PBS-control kidneys (Figure 7).
DISCUSSION
The effector phase of crescentic GN, including the anti-GBM
disease, clinically pursues a rapidly progressive course and
is thought to be driven by autoantibodies as well as
T-cell–mediated immunity. Three important findings emerge
from our study of the mouse EAG model: (1) crescentic GN
develops late after immunization with an accumulation of
macrophages and activated Th1 and Th17 lymphocytes in the
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Figure 5 |Renal T cells in experimental autoimmune
glomerulonephritis (EAG). (a) Quantification of immuno-
histochemical CD3 staining expressed as number of CD3þ cells
per mm2 renal cortex (control and week 10 vs. EAG Po0.05)
or (b) per 100 glomerular cross sections (P¼NS (not significant)).
(c) Fluorescence-activated cell sorting analysis of renal T cells.
Frequencies of renal CD4þ (left panel) and CD8þ T cells (right
panel) are given in relation to all acquired events. (d) Relative
intrarenal mRNA expression of chemokines and chemokine
receptors by real time reverse-transcriptase–PCR (for all panels:
control vs. EAG Po0.05). (a–d: each circle represents data of an
individual mouse; the bar gives the median.)
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kidneys; (2) glomerular autoantibody deposition occurs
prior to glomerular necrosis and crescent formation and
is accompanied by increased frequencies of IFNgþ CD4þ
T cells in the kidneys; (3) nephritic mouse kidneys contain
autoantigen-specific T cells producing IFNg upon a3IV-NC1
restimulation in vitro.
Induction of EAG in DBA/1 mice results in crescentic GN
within 9–13 weeks. The a3IV-NC1–specific humoral and
cellular immune response causes only little glomerular and
tubulointerstitial pathology until week 8. However, auto-
antibody deposition evolves during this period, which is
accompanied by progressive proteinuria. Apparently, within
a few days, kidneys in EAG progress from a preclinical stage
with marginal signs of renal inflammation to glomerular
necrosis and crescent formation in a large fraction of
glomeruli accompanied by severe tubulointerstitial damage.
Activation status of renal CD4+ T cells Frequencies of renal IFNγ+ and IL-17A+ CD4+ T cells
IFNγ  and IL-17A staining of renal CD4+ T cells
qPCR: cytokines
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As seen in human Goodpasture disease, the majority of
glomeruli show crescents of similar age, suggesting a rapid
and ‘synchronized’ disease progression.26
Antibodies against the immunized human-a3IV-NC1
protein are generated within days after the initial immuni-
zation25 and high titers are present within few weeks. These
antibodies show crossreactivity with mouse a3IV-NC1 and
can be detected along the GBM by week 5. By immuno-
fluorescence, the staining pattern is finely granular at all
time points studied, which is reflected by subepithelial
electron-dense deposits in the electron microscopic analysis.25
This ‘membranous’ pattern suggests in-situ immune complex
formation27–29 rather than deposition of circulating immune
complexes, which were also not detectable by a specific capture
assay. The mechanism of antibody binding in the EAG mouse
model is not completely clear. In the mouse, the antibody
epitope relevant for human disease is protected by sulfilimine
bonds and is not accessible.9 Both intra- and intermolecular
epitope spreading has been documented in the EAG rat model
and this mechanism presumably has an important role for the
mouse model as well.22,24,30
In the clinical stage of mouse EAG, the vast majority of the
inflammatory cells are macrophages with T-cell infiltration
less pronounced. In the tubulointerstitium, we found a
threefold increase in T-cell numbers at 10 weeks after primary
immunization and a fourfold increase in EAG mice. By
contrast, there was no difference in the numbers of
glomerular T cells. Renal T-cell distribution is different in
the rat model of EAG, in which an influx of glomerular T
cells is well documented.31 Although endocapillary hypercel-
lularity is not a common feature of human anti-GBM GN,32
increased numbers of T cells and macrophages have been
described in biopsies, both in the glomeruli as well as
extensively in the interstitium.33–35
In EAG, renal T cells almost exclusively show an activated
effector phenotype, which differs from the phenotype of
T cells isolated from spleen or lung of the same mice. Consis-
tent with the recruitment of activated T cells, enhanced
mRNA levels of the T-cell–attracting chemokines CXCL9,
CXCL10, CCL3, CCL4, and CCL5, as well as the correspond-
ing chemokine receptors CXCR3 and CCR5, are found, sug-
gesting a regulated trafficking of Th1 cells (CXCR3þ CCR5þ )
and macrophages (CCR5þ ) into the inflamed kidneys.36
Upon polyclonal stimulation of renal cells, IFNg– and
IL-17A–producing CD4þ T cells are detected, indicating the
presence of Th1 and Th17 cells, respectively. Both Th1 and
Th17 cells have been implicated in the development of EAG
and generally in anti-GBM disease.12,37–44 DBA/1 mice
immunized with a3IV-NC1 develop a strong Th1 antibody
response and spleen cells restimulated in vitro secrete IFNg.25
a3IV-NC1–specific cell lines isolated from immunized WKY
rats had a Th1 phenotype secreting IFNg but not IL-4, and
transfer resulted in crescentic GN.12 We detected renal Th1
cells present already in the preclinical stage of the disease and
the final stage was characterized by enhanced local mRNA
concentration for IFNg and a dominant accumulation of
macrophages, which are a main target of IFNg from Th1
cells.45 By contrast, an increase in Th17 cells was only seen in
the final stage with severe renal inflammation. Granulocytes,
one of the principle targets of Th17 cells, remained at low
levels during the whole time course.46,47
The role of Th17 cells in EAG is not completely under-
stood. Kitching et al.37 reported a protective role for IFNg in
EAG induced in C57BL/6 mice. This group further showed
that Goodpasture antigen autoreactivity is driven by IL-23
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b
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and is independent of IL-12 in this model, indicating that
Th17 cells rather than Th1 cells are responsible for EAG
development.38 In both studies, kidney damage was reported
to be minimal, with crescents in only up to 2% in 3/8 wild-
type animals in the first study and no crescents were reported
in the second study. Thus, EAG in C56BL/6 mice only
presents as a very mild GN. Results from C57BL/6 mice,
therefore, do not necessarily exclude a role of Th1 cells in
more severe courses of EAG. In nephrotoxic serum nephritis,
a model of anti-GBM nephritis elicited by a planted antigen,
both a Th1 and a Th17 response have been shown to
contribute to renal damage and it appears quite possible that
both T-cell subsets contribute with distinct functions to
disease initiation and progression.39,41,48 Experiments with
cytokine-deficient mice backcrossed to the DBA/1 back-
ground will be necessary to sort out the contribution of Th1
and Th17 cells.
Antigen-specific T-cell activation within the kidney
provides a potential mechanism to augment the cellular
immune response during the effector phase of crescentic GN
as has been shown in other animal models of autoimmune
disease, such as experimental autoimmune encephalomyelitis
or collagen-induced arthritis.49–51 However, direct evidence
of antigen-specific T effector mechanisms in kidney diseases
is still scarce. Nephritogenic T-cell clones have been isolated
from kidneys in the context of MRL/lpr lupus nephritis and
chronic graft-versus-host disease.52,53 In the context of EAG,
adoptive transfer of an a3IV-NC1–specific rat CD4þ Th1 cell
line into syngenic WKY rats 24 h after challenge with
pertussis toxin resulted in EAG, which developed at a much
slower pace and with less severity compared with actively
immunized rats. Fluorescent labeling of the cells revealed an
accumulation of the cells in the kidneys and lungs at 24 h.
However, T-cell function during established crescentic GN
(day 65) was not studied.12
In our current study, we could isolate renal a3IV-
NC1–specific T cells that produce IFNg upon restimulation
in vitro. Accumulation of T cells in mouse EAG is largely
restricted to the tubulointerstitium and there are only limited
numbers of T cells within the glomeruli. It is therefore likely
that most renal a3IV-NCI–specific T cells are located in
the interstitium of EAG kidneys. Heymann et al.54 recently
reported that renal dendritic cells are able to present
glomerular antigen to Th cells in the interstitium.55 Thus,
glomerular damage in EAG could result in activation of
T cells specific for glomerular antigens, including a3IV-NC1,
by tubulointerstitial dendritic cells. In turn, these T cells
could recruit further T cells and macrophages, thereby initi-
ating the severe inflammatory reaction within the inter-
stitium and the switch from the preclinical to the clinical
stage of disease. It is well known that under inflammatory
conditions major histocompatibility complex class II mole-
cules in the kidney are upregulated on tubular and
endothelial cells.56,57 These, in addition to the dendritic cells
and macrophages, could provide a sustained activation of
specific T cells driving the fatal kidney destruction in the
clinical stage of EAG. Overall, such a scenario could explain
the initially slow and biphasic progression of kidney disease
in mouse EAG. A final proof of this concept would require
approaches for specific localization and manipulation of
autoreactive T cells within the kidney, which are currently not
available for the EAG model.
In summary, we show that crescentic GN occurs late during
the course of mouse EAG and is preceded by autoantibody
deposition and the presence of Th1 effector cells in the
kidneys. The inflammatory infiltrate contains Th1 cells
specific for the autoantigen a3IV-NC1. This could provide a
mechanism for the rapid amplification of the cellular immune
response in the clinical stage causing kidney destruction.
MATERIALS AND METHODS
Recombinant type IV collagen NC1 domains
Recombinant human type IV collagen NC1 domains (a3IV-NC1,
a1IV-NC1, and a2IV-NC1) as well as mouse a3IV-NC1 were
expressed in 293EBNA cells, purified by immunoaffinity chromato-
graphy and analyzed by sodium dodecyl sulfate-polyacrylamide
gel electrophoresis and enzyme-linked immunosorbent assay using
anti-Flag- (M2, Sigma, Taufkirchen, Germany), anti-a1IV-, and
anti-a3IV-antibodies (MAB1, MAB3, Wieslab, Lund, Sweden) and
Goodpasture sera as described previously.25
Animal experiments
Male DBA/1J mice (Charles River, Sulzbach, Germany) were housed
under specific pathogen-free conditions. Animal experiments
were conducted according to the German Animal Protection Law.
Mice were immunized subcutaneously in the back with 25mg
of recombinant human-a3IV-NC1 in 50 ml PBS emulsified in an
equal volume of complete Freund adjuvant containing 50 mg Myco-
bacterium tuberculosis H37RA (DIFCO, Detroit, MI) and boosted at
day 21, 35, and 49 subcutaneously with 25mg antigen in incomplete
Freund adjuvant (IFA, DIFCO, Detroit, MI). Control mice were
immunized with the same volume of PBS/complete Freund adjuvant
and were boosted with PBS/incomplete Freund adjuvant.
Mice were weighed 2–3 times per week and followed up for signs
of disease. A stress score was used to individually determine the time
point for sacrifice. Mice were scored for body weight (weight loss
o5%¼ 1; 5–10%¼ 5; 11–20%¼ 10; 420%¼ 20), general condition
(fur defects¼ 1; untended body orifices¼ 5; fur dirty, body orifices
wet or stuck together¼ 10; palsy, low body temperature¼ 20),
spontaneous behavior (unusual behavior, limited activity¼ 5; self
isolation, lethargy¼ 10; autoaggressive behavior¼ 20), and edema
(mild edema¼ 5; generalized edema¼ 10). Mild stress was defined
as a scoreo10, moderate stress as a score of 10–19, and severe stress
as a score X20. Mice with mild stress were observed on a daily
basis. Mice with moderate stress were followed up for up to 48 h. If
the condition did not improve the animal was killed. Mice with
severe stress were either killed or followed up for up to 24 h before
sacrifice. Organs were collected and processed for immunological
and histopathological analysis. Values of individually analyzed mice
killed owing to a critical stress score were combined and are
presented under the terms ‘EAG’.
Functional studies
Albuminuria was determined by enzyme-linked immunosorbent
assay (Mice-Albumin Kit, Bethyl, Montgomery, TX). Urinary
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creatinine was determined by standard laboratory methods. Blood
samples for BUN measurement were obtained at the time of sacrifice
and measured by standard laboratory methods. Serum anti-a3IV-
NC1 antibodies were detected by indirect enzyme-linked immuno-
sorbent assay as described.25 Circulating immune complexes were
determined with a semiquantitative enzyme-linked immunosorbent
assay kit for mouse immune complexes containing IgM, IgG, and
IgA (Alpha Diagnostic International, San Antonio, TX). The assay
was conducted as indicated by the manufacturer with 100-fold
serum dilutions and positive and negative control sera included in
the kit.
Histology and immunohistochemistry
Tissue fixed in 10% neutral-buffered formalin was routinely
processed and embedded in paraffin. The presence of fibrin in the
urinary space and crescent formation were assessed in a blinded
manner in 100 consecutive glomeruli per mouse using the periodic
acid Schiff–stained tissue sections.
Tubulointerstitial damage was assessed semiquantitatively in a
blinded manner (modified from Ophascharoensuk et al.58). For each
mouse, 20 consecutive high-power fields (HPFs) were scored for
signs of acute tubular necrosis or interstitial fibrosis with tubular
atrophy (no damage¼ score 0; damage in o5% of HPF¼ score 1;
damage in 5–o25% of HPF¼ score 2; damage in 25–50% of HPF¼
score 3; damage in 450% of HPF¼ score 4). The mean tubulo-
interstitial damage score was calculated and used for statistical
analysis.
Immunohistochemistry for CD3 (A0452; Dako, Hamburg,
Germany), F4/80 (BM8; BMA, Hiddenhausen, Germany), MAC2
(M3/38, Cedarlane Laboratories, Burlington, Canada), and IgG
(IgG (Hþ L), XSA, HRP; Kirkegaard & Perry, Gaithersburg, MD)
was performed as described.25,40 CD3þ cells were counted in
20 HPFs of kidney cortex as well as in 100 consecutive glomeruli of
each mouse in a blinded fashion. As it was difficult to individually
count F4/80þ cells in mice with severe EAG, the F4/80þ area was
quantified by morphometry using the AutoMeasure module of
AxioVision software (Zeiss, Jena, Germany). For each mouse,
photographs of eight consecutive cortical HPFs were measured.
Results are given as % F4/80þ area/area of photograph. MAC2þ
cells were counted in 100 consecutive glomeruli of each mouse.
IgG was scored semiquantitatively as described.25
For immunofluorescence, kidneys were fixed in 4% buffered
paraformaldehyde for 24 h, infiltrated with 20% sucrose, and snap
frozen in optimal cutting temperature. In all, 5 mm cryosections
were pretreated with citrate buffer, pH 6, for 5 min at 801C to
allow antigen retrieval. For IgG staining, sections were blocked with
5% goat serum (Vector Laboratories, Burlingame, CA, 30 min,
room temperature), and incubated with goat anti-mouse IgG-Cy3
(Jackson Immuno Research Laboratories, West Groove, PA, 1:1000
dilution, 30 min, room temperature). For complement C3 staining,
sections were blocked with 5% horse serum (Vector Laboratories,
30 min, room temperature) and incubated with goat anti-mouse
C3-FITC (Cappel Laboratories Organon Teknika, West Chester, PA,
1:200 dilution, 30 min, room temperature). IgG and C3 deposition
was semiquantitatively scored in 20 consecutive glomeruli as
negative, weak, moderate, or strong.
Real-time RT-PCR analysis
Total renal RNA was prepared from renal cortex and reverse
transcribed as described.40 Real-time PCR was performed using the
SYBR green technique with specific murine primers (primer
sequences available on request). All samples were run in duplicate
and normalized to 18S rRNA levels as described.40
Isolation of spleen lung and renal cells
Spleens were aseptically removed and placed in ice-cold PBS.
Spleens were gently pushed through a 70-mm cell strainer followed
by a 40-mm cell strainer (BD Biosciences, Heidelberg, Germany) to
obtain a single-cell suspension. Red cells were lysed and were
resuspended in RPMI1640 medium supplemented with 10% heat-
inactivated fetal bovine serum, glutamine, b-mercaptoethanol, and
gentamycin (complete RPMI1640 medium). Lungs and kidneys
were perfused with PBS and aseptically removed and placed in ice-
cold PBS. Organs were cut into small pieces and digested with
2 mg/ml collagenase D (Roche, Penzberg, Germany) and 100 mg/ml
DNAse I (Roche) in complete RPMI1640 medium. The tissue was
gently pushed through a 70-mm cell strainer followed by a 40-mm
cell strainer. Cells were washed and resuspended in complete
RPMI1640.
Flow cytometry
Fluorochrome-labeled antibodies against mouse CD3 (17A2 or
145-2C11), CD4 (GK1.5 or RM4-5), CD8a (53-6.7), CD11b
(M1/70), CD19 (1D3), CD44 (IM7), CD45 (30-F11), CD62L
(MEL-14), F4/80 (BM8), Gr-1 (RB6-8C5), Ly6c (AL-21), MCH
class II (M5/114.15.2), IFNg (XMG1.2), and IL-17A (TC11-18H10)
were purchased by R&D Systems (Wiesbaden, Germany),
Miltenyi Biotech (Bergisch-Gladbach, Germany), BD Biosciences,
or eBioscience (Frankfurt, Germany). Kidney, spleen, and lung cells
were incubated for 5 min at 41C with rat serum and anti-CD16/
CD32 antibody (2.4G2) to block unspecific antibody binding. Cells
were subsequently stained for 25 min at 41C with fluorochrome-
conjugated antibodies. Cells were acquired with a FACScalibur or a
FACScanto and results were analyzed using the CellQuest or the
Diva Software (all purchased from BD Biosciences).
For determination of cytokine production, cells were incubated
at 371C, 5% CO2 for 4 h with phorbol 12-myristate 13-acetate
(5 ng/ml; Sigma) and ionomycin (1 mg/ml; Calbiochem-Merck,
Darmstadt, Germany) in complete RPMI1640 medium. After
30 min of incubation, Brefeldin A (10 mg/ml; Sigma) was added.
Subsequently, cells were extracellularly and intracellularly stained
and analyzed as described previously.59
Elispot assays
Spleen cells from naive DBA/1J mice were incubated with
mouse anti-major histocompatibility complex class II MicroBeads
(Miltenyi Biotec). Major histocompatibility complex class IIþ cells
were isolated by magnetic separation on a MACS MS column
(Miltenyi Biotec, Bergisch-Gladbach, Germany) according to the
manufacturer’s instructions. Kidneys of EAG or control mice
were aseptically removed and placed in ice-cold Hank’s buffered
salt solution. Kidney cells were separated by a density gra-
dient centrifugation on Lympholyte-M (Cedarlane, Burlington,
Canada). Isolated renal cells were incubated with mouse CD90
(Thy1) microbeads, and CD90þ cells were enriched by magnetic
separation on two consecutive MACS MS columns (Miltenyi
Biotec).
Elispots were performed on 96-well MultiScreen filter plates
(Millipore, Bedford, MA) using a paired antibody set for mouse
IFNg, avidin-HRP, and AEC substrate (BD Biosciences) according to
the manufacturer’s instructions. Per well 5000 renal cells recovered
from the CD90 MACS columns were mixed with 2 105 splenocytes
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recovered from the MHCII MACS column. In all, 5000 renal cells
alone or 2 105 splenocytes alone were used as controls. Duplicate
or triplicate wells were left unstimulated, stimulated with 2 mM
a3IV-NC1, or stimulated with 2 mM a1IV-NC1 or a2IV-NC1. Cells
were cultured in serum-free X-Vivo 20 medium (BioWhittaker,
Walkersville, MD) for 40 h. Cells were washed off and Elispots were
developed.
The wells of each filter plate were photographed in groups of
4–6 wells with a digital camera (Nikon, Du¨sseldorf, Germany).
Images of the individual wells were separated and counted
automatically using the AutoMeasure module of AxioVision soft-
ware (Zeiss, Jena, Germany).
Data are presented as DIFNg spots, which is the number of IFNg
spots in renal cells mixed with antigen-presenting cells minus the
number of background IFNg spots in antigen-presenting cells alone.
In order to obtain a larger number of independent data points for
statistical analysis of the IFNg Elispot experiments, the data of PBS-
immunized (n¼ 4) and naive control mice (n¼ 6) were combined,
as well as the data of renal cells stimulated with control proteins
a1IV-NC1 (n¼ 3) and a2IV-NC1 (n¼ 4).
Statistical analysis
Differences between three or more groups were confirmed by the
Kruskal–Wallis test and followed by a Mann–Whitney U test to
compare two groups with each other. In some experiments the
Mann–Whitney U test could not be applied owing to repeated zero
values in the control mice. In these cases the Wilcoxon signed-rank
test was used instead. Experiments that did not yield enough inde-
pendent data points for statistical analysis due to the experimental
setup were repeated three times. A representative experiment or the
results of all three experiments are shown.
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